CUROSURF is the #1 surfactant worldwide, and the number of infants treated continues to grow.

If you haven’t used CUROSURF in your NICU, you may be surprised to learn some interesting facts about how many NICUs in the US and worldwide are experiencing CUROSURF.

• More infants are treated with CUROSURF each year than with any other surfactant⁵
• The number of hospitals using CUROSURF has nearly tripled across the US since 2004⁵
• 20 years of clinical practice with over 1 million infants⁶

Ongoing research that keeps pace with clinical practice

• Safety and efficacy established in 17 clinical trials, evaluating over 4000 patients⁶
• Growing clinical portfolio of over 30 published articles⁶
• The surfactant most widely studied for use with less invasive ventilation strategies^1,6
• Continuing support dedicated to the advancement of neonatology research and the treatment of RDS

Download an overview of our broad clinical portfolio

CUROSURF Product Monograph.

For further reading, consider exploring these other published studies.

Clinical studies have not established that fewer doses, lower volume, or longer dosing intervals result in superior safety or efficacy based on clinically relevant end points.

Next: Experience CUROSURF in your NICU

Further reading

• Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. American Journal of Perinatology. 2004;21:109-119.
• Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatrica. 2005;94:779-784.
• Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics. 1988;82:683-691.
• Wiseman LR, Bryson HM. Porcine-derived lung surfactant: a review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf^®) in neonatal respiratory distress syndrome. Drugs. 1994;48:386-403.
• Verder H, Robertson B, Greisen G, et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. New England Journal of Medicine. 1994;331:1051-1055.
• Schürch S, Schürch D, Curstedt T, Robertson B. Surface activity of lipid extract surfactant in relation to film area compression and collapse. Journal of Applied Physiology. 1994;77:974-986.
• Speer CP, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Archives of Disease in Childhood. 1995;72:F8-F13.
• Verder H, Albertsen P, Ebbesen F, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks’ gestation. Pediatrics. 1999;103:1-6.
• Ingimarsson J, Björklund L, Jonson B, et al. A radio-isotope technique for visualisation of exogenous surfactant spreading in immature lamb lungs at birth. Biology of the Neonate. 2000;77(suppl1):24.
• Taeusch HW, Lu K, Ramierez-Schrempp D. Improving pulmonary surfactants. Acta Pharmacologica Sinica. 2002;23(suppl):11-15.
• Dani C, Bertini G, Pezzati M, Cecchi A, Caviglioli C, Rubaltelli FF. Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks’ gestation. Pediatrics. 2004;113:e560-e563.
• Gerdes JS, Seiberlich W, Sivieri EM, et al. An open-label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources. Journal of Pediatric Pharmacology and Therapeutics. 2006;11:92-100.
• Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M. Implementation of surfactant treatment during continuous positive airway pressure. Journal of Perinatology. 2007;27:422-427.

References: 1. CUROSURF^® (poractant alfa) Intratracheal Suspension prescribing information, Cornerstone Therapeutics Inc, September 2009. 2. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. Am J Perinatol. 2004;21:109-119. 3. Speer CP, Gefeller O, Groneck P, et al. Arch Dis Child. 1995;72:F8-F13. 4. Malloy CA, Nicoski P, Muraskas JK. Acta Paediatr. 2005;94:779-784. 5. IMS DDD Lung Surfactant Market Purchases May 2004 to December 2009. 6. Data on file, Chiesi Farmaceutici, S.p.A. and Cornerstone Therapeutics Inc.